194 related articles for article (PubMed ID: 28027771)
1. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT.
Ohno Y; Fujisawa Y; Koyama H; Kishida Y; Seki S; Sugihara N; Yoshikawa T
Eur J Radiol; 2017 Jan; 86():83-91. PubMed ID: 28027771
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.
Seki S; Fujisawa Y; Yui M; Kishida Y; Koyama H; Ohyu S; Sugihara N; Yoshikawa T; Ohno Y
Magn Reson Med Sci; 2020 Feb; 19(1):29-39. PubMed ID: 30880291
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy.
Ohno Y; Koyama H; Fujisawa Y; Yoshikawa T; Seki S; Sugihara N; Sugimura K
Eur J Radiol; 2016 Jan; 85(1):176-186. PubMed ID: 26724663
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
Ohno Y; Fujisawa Y; Sugihara N; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2017 Nov; 209(5):W253-W262. PubMed ID: 28929810
[TBL] [Abstract][Full Text] [Related]
5. Solitary pulmonary nodule: Comparison of quantitative capability for differentiation and management among dynamic CE-perfusion MRI at 3 T system, dynamic CE-perfusion ADCT and FDG-PET/CT.
Ohno Y; Fujisawa Y; Yui M; Takenaka D; Koyama H; Sugihara N; Yoshikawa T
Eur J Radiol; 2019 Jun; 115():22-30. PubMed ID: 31084755
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
7. Comparison of quantitatively analyzed dynamic area-detector CT using various mathematic methods with FDG PET/CT in management of solitary pulmonary nodules.
Ohno Y; Nishio M; Koyama H; Fujisawa Y; Yoshikawa T; Matsumoto S; Sugimura K
AJR Am J Roentgenol; 2013 Jun; 200(6):W593-602. PubMed ID: 23701089
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
10. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
11. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
12.
Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
[TBL] [Abstract][Full Text] [Related]
13. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
[TBL] [Abstract][Full Text] [Related]
14. Solitary pulmonary nodules: Comparison of dynamic first-pass contrast-enhanced perfusion area-detector CT, dynamic first-pass contrast-enhanced MR imaging, and FDG PET/CT.
Ohno Y; Nishio M; Koyama H; Seki S; Tsubakimoto M; Fujisawa Y; Yoshikawa T; Matsumoto S; Sugimura K
Radiology; 2015 Feb; 274(2):563-75. PubMed ID: 25203128
[TBL] [Abstract][Full Text] [Related]
15. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
Hwang SH; Yoo MR; Park CH; Jeon TJ; Kim SJ; Kim TH
Eur Radiol; 2013 Jun; 23(6):1573-81. PubMed ID: 23300040
[TBL] [Abstract][Full Text] [Related]
18. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
19. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
Vera P; Mezzani-Saillard S; Edet-Sanson A; Ménard JF; Modzelewski R; Thureau S; Meyer ME; Jalali K; Bardet S; Lerouge D; Houzard C; Mornex F; Olivier P; Faure G; Rousseau C; Mahé MA; Gomez P; Brenot-Rossi I; Salem N; Dubray B
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1057-65. PubMed ID: 24562641
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
